Finoriq research workspace
Janux Therapeutics, Inc. (JANX) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Janux Therapeutics, Inc. (JANX).
Company Snapshot
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Company
- Janux Therapeutics, Inc. (JANX)
- Ticker
- JANX
- Market Cap
- $985.2M
- Latest Price
- $16.16
- Industry
- Biotech & Pharma
Janux Therapeutics, Inc. (JANX) Recent Insider Transactions
Recent market insider transaction records indexed for Janux Therapeutics, Inc. (JANX).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| McIver ZachariahChief Medical Officer | S | Disposed | -$37,263 | 2026-01-02 |
| Dobek MariaVice President, Accounting | S | Disposed | -$20,073 | 2026-01-02 |
| DiRaimondo ThomasChief Scientific Officer | S | Disposed | -$34,394 | 2026-01-02 |
| Winter Charles M.Chief Technical Officer | S | Disposed | -$32,966 | 2026-01-02 |
| Meyer Andrew HollmanChief Business Officer | S | Disposed | -$25,799 | 2026-01-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.